Regulation of amylin release from cultured rabbit gastric fundic mucosal cells

Ian LP Beales*1,2 and John Calam3

Address: 1Gastrointestinal Research Unit, Department of Physiology and Cell Biology, School of Medicine, Health Policy and Practice, University of East Anglia, Norwich NR4 7JU, United Kingdom, 2Department of Gastroenterology, Norfolk and Norwich University Hospital NHS Trust, Norwich NR4 7JU, United Kingdom and 3Department of Medicine, Imperial College School of Medicine, Hammersmith Hospital, London W12 0NN, United Kingdom

Email: Ian LP Beales* - i.beales@uea.ac.uk; John Calam - j.calam@ic.ac.uk

* Corresponding author

Abstract

Background: Amylin (islet amyloid polypeptide) is a hormone with suggested roles in the regulation of glucose homeostasis, gastric motor and secretory function and gastroprotection. In the gastric mucosa amylin is found co-localised with somatostatin in D-cells. The factors regulating gastric amylin release are unknown. In this study we have investigated the regulation of amylin release from gastric mucosal cells in primary culture. Rabbit fundic mucosal cells enriched for D-cells by counterflow elutriation were cultured for 40 hours. Amylin and somatostatin release over 2 hours in response to agonists were assessed.

Results: Amylin release was significantly enhanced by activation of protein kinase C with phorbol-12-myristate-13-acetate, adenylate cyclase with forskolin and elevation of intracellular calcium with A23187. Cholecystokinin (CCK), epinephrine and glucagon-like peptide-1 (GLP-1) each stimulated amylin release in a dose-dependent manner. Maximal CCK-stimulated release was greater than either epinephrine or GLP-1, even when the effects of the latter two were enhanced by isobutylmethylxanthine. Stimulated amylin release was significantly inhibited by carbachol (by 51–59%) and octreotide (by 33–42%). Somatostatin release paralleled that of amylin.

Conclusions: The cultured D-cell model provides a means of studying amylin release. Amylin secretion is stimulated by receptor-dependent and -independent activation of Ca2+/protein kinase C and adenylate cyclase pathways. Inhibition involves activation of muscarinic receptors and auto-regulation by somatostatin.

Background

Amylin (islet amyloid polypeptide) is a 37-amino acid peptide predominantly expressed in the pancreatic islets of Langerhans [1,2]. Amylin has also been localised throughout the gastrointestinal tract [3] and in the brain [4]. Much recent work has focused on the physiology of pancreatic amylin; the peptide appears to be co-stored and co-secreted with insulin in pancreatic B-cells [5,6], a smaller proportion is co-localised with somatostatin in pancreatic D-cells [7].

Amylin is believed to function as a hormone regulating glucose homeostasis. Amylin inhibits basal and insulin-stimulated glycogen synthesis in rat skeletal muscle [8,9]; it inhibits insulin, somatostatin and glucagon secretion from isolated pancreatic islets and intact perfused...
pancreas and it reduces post-prandial glucagon and insulin secretion [10–12]. Amylin may also contribute to glycaemic control by slowing gastric emptying [13]. It addition to these physiological roles, amylin is believed to play significant role in the pathogenesis of diabetes mellitus. It is the major component of the amyloid deposits in the islets of patients with non-insulin dependent diabetes mellitus [1,2] and deficiency of amylin may contribute to the failure of glycaemic control typical of insulin-dependent diabetes [14] and in animal studies amylin itself appears to induce insulin resistance [15].

A variety of physiological effects on the gastrointestinal tract have also been described. Parenteral administration of amylin has an anorectic effect [13], in addition to significantly reducing gastric emptying [16]. A protectant action against reserpine-, and serotonin-induced gastropathy has been described [17]. Intravenous amylin is a potent inhibitor of basal, pentagastrin and 2-deoxy-D-glucose stimulated gastric acid secretion in the rat [18] and amylin reduced acid secretion in the isolated mouse stomach preparation [19]. A stimulant effect on serum gastrin has also been reported, although this may have been secondary to the inhibition of acid secretion [20]. In keeping with these actions amylin-binding sites have been detected in rat gastric fundic mucosa [21]. Within the gastrointestinal tract amylin appears to co-localise with other gastrointestinal peptides. Using in situ hybridisation, immunofluorescence and immunocytochemistry, Mulder et al showed that amylin predominantly co-localised with somatostatin in the D-cells of rat and mouse antral mucosa and rat fundic mucosa [22]. A minority of amylin co-localised to separate populations of gastrin-containing cells in the antrum and PYY-containing cells in the fundus. Studies in PDX-1 deficient mice (which fail to develop G-cells) demonstrated no alteration in gastric amylin expression, confirming predominant expression of amylin within D-cells [23]. These data showing the presence of amylin and amylin receptors, coupled with the pharmacological effects, suggested that amylin might have a paracrine and/or endocrine regulatory and pathophysiological role in the gastric mucosa. However there are no studies exploring the processes involved in gastric amylin secretion. Such data are a prerequisite for further understanding of gastric amylin physiology. Primary cultures of gastric and intestinal endocrine cells have been utilised to examine the physiological and pathophysiological control of several gastrointestinal peptides including gastrin, somatostatin, glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) [24–30]. The co-localisation of amylin with somatostatin makes the gastric fundic D-cell preparation a useful model to examine the control of amylin secretion at the cellular level.

In this study we have examined receptor-dependant and receptor-independent regulation of amylin secretion from cultured rabbit gastric fundic mucosal cells. Cholecystokinin, glucagon-like peptide-1 and epinephrine stimulated amylin release in a dose dependant manner and the muscarinic receptor agonist carbachol and somatostatin receptor agonist octreotide inhibited amylin release. Somatostatin and amylin release occurred in parallel.

**Results**

**Receptor-independent stimulation of peptide release**

To initially assess whether amylin release could be detected from the cultures of rabbit fundic cells, potent receptor-independent stimuli were used [26]. The total cell content (TCC) of amylin in the cultured cell preparation (801 ± 151 fmol/well) was approximately 4 to 5-fold lower than that of somatostatin (3 768 ± 1325 fmol/well). Significant stimulation of amylin release occurred with the active phorbol ester (phorbol-12-myristate-13-acetate, PMA) which activates protein kinase C (PKC), activation of adenylate cyclase with forskolin and elevation of intracellular calcium with the ionophore A23187 (Figure 1). The phorbol ester was the most potent stimulant, leading to 8.5 fold increase in amylin release (basal release 2.14 ± 0.8% increasing to 18.5 ± 1.4% of TCC). Forskolin increased release 3.3 fold (maximal release 7.2 ± 1.4% of TCC) and A23187 by 1.8 fold (3.8 ± 0.5% TCC), these were markedly less potent than PMA. There were no significant differences between the patterns of somatostatin and amylin release (Figure 1).

**Receptor-dependent stimulation**

Previous studies have demonstrated that CCK is a potent stimulant of somatostatin release [26]. This was confirmed here. CCK dose-dependently stimulated release of amylin from the cultured cells (Figure 2). Maximal stimulation, a 2.75 fold increase, 2.1 ± 0.7% basal release increased to 5.9 ± 0.8% TCC, occurred with CCK 10 nM. A similar dose response pattern was seen for CCK-stimulated somatostatin release although maximal release was relatively higher for somatostatin (4.4 fold, 1.1 ± 0.1% to 5.2 ± 0.7% TCC) than amylin (Figure 2).

Activation of adenylate cyclase-coupled receptors with either epinephrine or glucagon-like peptide-1 led to a dose-dependent small increase in both somatostatin (maximal increase 1.44 and 1.35 fold respectively) and amylin release (1.36 and 1.25 and fold respectively) (Figures 3 and 4).

The responses to epinephrine and GLP-1 were enhanced by co-administration with the phosphodiesterase inhibitor isobutylmethylxanthine (IBMX) (100 µM). Basal amylin release was 2.0 ± 0.2% TCC and maximal IBMX-enhanced release 3.2 ± 0.2% TCC with epinephrine at 100 µM.
µM and 3.2 ± 0.3% TCC with GLP-1 at 10 nM. Basal somatostatin release (1.1 ± 0.1% TCC) increased to 2.7 ± 0.1% TCC with epinephrine + IBMX and 2.1 ± 0.4% TCC with GLP-1 + IBMX. These were still significantly less than CCK-stimulated release. There were no differences in the pattern or ratio of somatostatin and amylin responses (Figures 3 and 4).

**Inhibitory regulation of amylin release**

Treatment with the somatostatin analogue octreotide produced small but non-significant reductions in both basal amylin (by 14%) and basal somatostatin (by 18%) secretion (Figure 5). Carbachol had no obvious effect on either basal amylin or somatostatin secretion (Figure 5). CCK-stimulated amylin release was significantly inhibited by octreotide (by 42%) and the muscarinic agonist carbachol (by 51%). Similarly epinephrine (with IBMX)-stimulated amylin release was inhibited by 33% by octreotide and 59% by carbachol (both P < 0.05). As shown in figure 6, a similar pattern was seen with somatostatin release.

**Discussion**

This is the first study to examine the release of amylin from gastric mucosa at the cellular level. Results demonstrated that amylin was not only stored in gastric mucosal cells but also that putative physiological agonists regulated release of the peptide. Previous studies have localised amylin to the stomach using Northern blotting [31,32], immunocytochemistry [33], radioimmunoassay [3] and **in situ** hybridisation [22] but the release of gastric amylin has not been demonstrated previously.

The majority of gastric fundic amylin appears to be localised with somatostatin within D-cells [22] Therefore we have used the cultured rabbit D-cell model to investigate the agents controlling cellular release of amylin and to compare this to somatostatin secretion.
Initial studies were performed with potent agents known to directly activate peptide secretion from endocrine cells in a receptor-independent manner [26] Phorbol esters (such a PMA) directly activate protein kinase C in the inner layer of the cell membrane; this in turn activates the cellular processes required for exocytosis. PMA was a potent stimulant of both somatostatin and amylin secretion. The calcium ionophore A23187, which increases levels of intracellular calcium ([Ca^{2+}]_{i}) also stimulated amylin release; although it was significantly less potent than PMA. This is similar to the responses seen in human antral [26] and canine fundic D-cells [30] where it is believed the rise in [Ca^{2+}]_{i} is mainly facilitative rather than directly stimulating secretion. Direct activation of adenyly cyclase with forskolin also stimulated amylin release. Therefore the initial studies demonstrated that amylin release could be stimulated by activation of either of the two main intracellular signalling pathways known to enhance peptide secretion. Having determined that these pathways were active, we explored which physiolog-
ical agents could stimulate amylin secretion in a receptor-dependent manner.

Cholecystokinin-8 produced a dose-dependent increase in amylin and somatostatin secretion. CCK is known to be a potent in vitro stimulant of somatostatin release from antral and fundic D-cells [26,30,34]. A similar dose response was seen for amylin, although the overall increment was slightly greater for somatostatin than amylin. Further studies will be needed to determine whether this represents a separate pool of somatostatin specifically secreted following stimulation with CCK. Fundic D-cells appear to express both the CCK-1 (CCK\(\alpha\)) and CCK-2 (gastrin/CCK\(\beta\)) receptors [35]. Activation of these receptors triggers the activation of phospholipase C, release of diacylglycerol and inositol 1,4,5-trisphosphate and subsequent elevation of \([\text{Ca}^{2+}]\) and activation of PKC, leading to peptide release [36]. These results are consistent with the results for A23187 and PMA stimulation. Therefore it appears that CCK may act as a physiological stimulant of amylin release.

Epinephrine and GLP-1 produced small dose-dependent increases in amylin and somatostatin secretion. This effect could be enhanced by co-treatment with the phosphodiesterase inhibitor IBMX, which inhibits cAMP breakdown and amplifies responses generated by adenylyl cyclase coupled receptors. However the responses were still significantly less that those seen with activation of the \(\text{Ca}^{2+}/\text{PKC}\) pathway by either CCK or PMA. Similar differences in the sensitivities have been described in human antral [26] and canine fundic [30] D-cells.

The predominant inhibitory influences described thus far on fundic D-cells are muscarinic agonists [37,38] and autoregulation by somatostatin itself [39,40]. The responses reported here are in keeping with the data on somatostatin release from canine fundic D-cells [30,37]. In contrast, muscarinic receptors are stimulatory to antral D-cells [41], probably reflecting a specific difference in function. The current study confirmed the inhibitory actions of both the somatostatin-analogue octreotide and muscarinic agonist carbachol against somatostatin release. A similar inhibition of stimulated amylin release was seen. This suggests that in vivo inhibition of amylin release involves parasympathetic input and autocrine regulation by somatostatin.

Under all conditions studied somatostatin and amylin were secreted in parallel, as may be expected if they are co-stored in secretory granules. Insulin and amylin are co-secreted from pancreatic \(\beta\)-cells, secretion normally occurs in parallel [42–44] but differential secretion has been reported in experiment models of diabetes mellitus [45,46]. Further studies will be needed to further define the relationship between the secretion and actions of gastric amylin and somatostatin. In isolated pancreatic islets the two peptides appear to have a co-operative role in regulating peptide secretion: combined immunoneutralisation of amylin and somatostatin resulted in greater enhancement of insulin and glucagon secretion than neutralisation of either alone [10]. It will be interesting to examine whether similar results are seen with gastric functions.

Post-prandial release of intestinal CCK and GLP-1 inhibit gastric emptying and acid secretion [13,47]. These effects are thought to be mediated at least in part via intermediates released from the D-cell rather than by directly inhibiting the acid-secreting parietal cell [48]. It was believed that somatostatin was the sole intermediate but the results of the current study suggest that paracrine regulation by amylin of parietal, ECL- and other endocrine cells may have a role in the integrative responses to meals. The amylin-induced inhibition of histamine released from rat fundic mucosal segments in vitro was mediated via increased somatostatin release [19] but using a selective somatostatin receptor antagonist Rossowski et al.
showed *in vivo* in rats that a portion of the acid-inhibitory actions of both amylin and the related peptide adrenomedullin were somatostatin-independent [49]. The specific roles of amylin in gastric physiology require further elucidation but these data suggest that locally released amylin is directly capable of regulating mucosal functions.

The responses to epinephrine and carbachol suggest that autonomic innervation can regulate the secretion of amylin. The overall balance *in vivo* would then depend on the relative input of the inhibitory muscarinic and stimulatory adrenergic systems, combined with circulating endocrine and local paracrine and possibly luminal factors.

**Conclusion**

This study describes the initial characterisation of the factors regulating gastric amylin release. We have demonstrated that amylin release can be stimulated by receptor-dependent stimulation of either of the Ca²⁺/PKC and adenylate cyclase/CAMP pathways and that physiologically relevant peptides and neural mediators can enhance amylin release. This supports the hypothesis that amylin may module gastric mucosal function. This study confirms that short-term cultures of cells enriched by elutriation will provide a model for exploring the pathophysiological release of gastric amylin and provide a route of further understanding the role of amylin in regulation of gastric motor and secretory function.

**Methods**

**Materials**

Matrigel was obtained from Universal Biologicals (London, UK), octreotide from Novartis (Surrey, UK) and Ham’s F12/Dulbecco’s modified Eagle’s culture medium (50:50, v:v), glutamine, Hanks balanced salt solution and foetal calf serum were purchased from Gibco (Paisley, UK). Sulphated cholecystokinin-8 (CCK), human GLP-1 (50:50, v:v), glutamine, Hanks balanced salt solution and foetal calf serum were purchased from Gibco (Paisley, UK). Sulphated cholecystokinin-8 (CCK), human GLP-1 and all other reagents were obtained from Sigma (Poole, UK).

**Cell isolation and culture**

Primary cultures of rabbit gastric fundic mucosal cells enriched for D-cells were obtained as described previously [39,48]. Briefly, rabbit fundic mucosa was subjected to sequential EDTA and collagenase digestion. The resulting cell suspension was enriched for D-cells by counterflow elutriation using a Beckman JE 5.0 standard rotor as previously described. The D-cell enriched fraction was resuspended in complete culture medium (Ham’s F12/Dulbecco’s modified Eagle’s culture medium (50:50, v:v), containing 2 mM glutamine, 10 mM HEPES pH 7.4, 0.22% NaHCO₃, 10% foetal calf serum, 1 mg/l hydrocortisone, 8 mg/l insulin, 100 mg/l penicillin, 100 mg/l gentamicin, 100 mg/l streptomycin) and cultured on Matrigel-coated 24 well tissue culture plates [50] at a density of 1 × 10⁶ cells/well for 40 hours in an atmosphere of 5% CO₂, 95% air at 37°C.

**Release Studies**

Cultured cells were washed 3 times in release medium (Earl’s balanced salt solution containing 0.1% bovine serum albumin, 10 mM HEPES pH 7.4) to remove dead and non-adherent cells. A further 1 ml of release medium was added containing test agonists and cells incubated for 2 hours at 37°C in an atmosphere of 5% CO₂, 95% air. After the release period, the conditioned media was aspirated and centrifuged to remove non-adherent cells. Total cellular content of peptide was extracted by boiling in 1 ml in distilled water. Conditioned media and cell extracts were stored at -70°C until assayed for peptide content [30].

**Peptide measurement**

Somatostatin concentrations were assessed by radioimmunoassay (RIA) with antiserum K2, as described previously [39]. Half-maximal inhibition of binding occurred at 2 fmol / tube and the intra-assay and inter-assay variation were 7% and 8% percent respectively. Amylin concentrations were measured by direct ELISA (Peninsula Laboratories, Belmont, CA, USA), according to the manufacturer’s instructions. The assay has a range of 0.04–2 ng / ml, and intra-assay and inter-assay variation of < 5% and <14% respectively. The antibody used has 100% cross reactivity with amylin and amylin-amide but < 1% cross reactivity with CGRP and negligible reaction with other biologically active peptides. All experimental samples from a single animal preparation were assayed in the same RIA or ELISA.

**Statistical analysis**

Peptide release during the 2-hour period was expressed as the percentage of the total cell content (TCC) of that peptide. Each experimental condition was tested in duplicate and results from a single animal preparation were regarded as N = 1. Results are expressed as the mean ± SEM of 3–6 separate animal preparations. Each 24 well plate always included control (basal) wells and positive stimulants. Peptide release by stimulants was compared to the basal release on the relevant 24 well plate. One-way analysis of variance and Student’s paired t-test were used to determine significance. A P value of < 0.05 was regarded as significant.

**List of abbreviations**

CCK, cholecystokinin; ECL-, enterochromaffin-like; GLP-1, glucagon-like peptide-1; IAPP, islet amyloid polypeptide; IBMX, isobutylmethylxanthine; PKC, protein kinase C; PMA, phorbol-12-myristate-13-acetate, TCC, total cell content.
Authors’ Contributions

ILPB conceived and designed the study, performed the cell isolation, culture, release experiments, immunoassays and wrote draft and final versions of the manuscript. The late JC conceived the study and co-wrote the first manuscript draft.

Acknowledgments

This work was supported in part by a Medical Research Council training fellowship for ILPB.

Some of the data were presented in abstract form at the United European Gastroenterology Week in Birmingham 1997.

References

1. Westermark P, Wernstedt C, Wilander E and Sletten K: A novel peptide in the calcitonin gene-related peptide family as an amyloid fibril protein in the endocrine pancreas. Biochem Biophys Res Commun 1986, 140:827-31.

2. Cooper GJ, Willis AC, Clark A, Turner RC, Sim RB and Reid KB: Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci U S A 1987, 84:6283-32.

3. Miyazato M, Nakazato M, Shiomi K, Aburaya J, Toshimori H, Kangawa K, Matsuo H and Matsukura S: Identification and characterization of islet amyloid polypeptide in mammalian gastrointestinal tract. Biochem Biophys Res Commun 1991, 181:283-300.

4. Chance WT, Balasubramaniam A, Zhang FS, Wimalawansa S and Fisher JE: Anorexia following the intrahypothalamic administration of amylin. Brain Res 1991, 539:352-4.

5. Lukinius A, Wilander E, Westermark GT, Engstrom U and Westermark P: Co-localization of islet amyloid polypeptide and insulin in the B cell secretory granules of the human pancreatic islets. Diabetologia 1989, 32:240-4.

6. Johnson KH, O’Brien TD, Hayden DW, Jordan K, Ghoufral HK, Mahoney WC and Westermark P: Immunolocalization of islet amyloid polypeptide (IAPP) in pancreatic beta cells by means of peroxidase-antiperoxidase (PAP) and protein A-gold techniques. Am J Pathol 1988, 130:1-8.

7. Mulder H, Lindh AC and Sundler F: Islet amyloid polypeptide gene expression in the endocrine pancreas of the rat: a combined in situ hybridization and immunocytochemical study. Cell Tissue Res 1993, 274:467-74.

8. Leighton B and Cooper GJ: Pancreatic amylin and calcitonin gene-related peptide cause resistance to insulin in skeletal muscle in vitro. Nature 1988, 335:632-5.

9. Frontoni S, Choi SB, Banduch D and Rossetti L: In vivo insulin resistance induced by amylin primarily through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle. Diabetes 1991, 40:568-73.

10. Wang F, Adrian TE, Westmark GT, Ding X, Gaslander T and Perment J: Islet amyloid polypeptide tonally inhibits beta-, alpha- and delta-cell secretion in isolated rat pancreatic islets. Am J Physiol 1999, 276:E19-24.

11. Wang ZL, Bennet WM, Ghatzi MA, Byfield PG, Smith DM and Bloom SR: Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid polypeptide on insulin release from perfused rat islets. Diabetes 1993, 42:330-5.

12. Degano P, Silvestre RA, Salas M, Peiro E and Marco J: Amylin inhibits glucose-induced insulin secretion in a dose-dependent manner. Study in the perfused rat pancreas. Regul Pept 1993, 43:91-6.

13. Reidelberger RD, Armeo U, Granquist L and Perment J: Comparative effects of amylin and cholecytokinin on food intake and gastric emptying in rats. Am J Physiol Regul Integ Comp Physiol 2001, 280:R605-11.

14. Kruger DF, Gatcomb PM and Owen SK: Clinical implications of amylin and amylin deficiency. Diabetes Educ 1999, 25:389-97.

15. Schmitz O, Nyholm B, Juul CB, Lund S and Orskov L: Aspects of secretion and actions of amylin: interplay between amylin and other hormones. J Endocrinol Invest 1999, 22:33-6.

16. Clementi G, Caruso A, Cutilti VM, de Bernardis E, Prato A, Amico Rosas M and Amico-Rosas M: Amylin given by central or peripheral routes decreases gastric emptying and intestinal transit in the rat. Expopatia 1996, 52:677-9.

17. Clementi G, Caruso A, Cutilti VM, Prato A, de Bernardis E and Amico-Rosas M: Effect of amylin in various experimental models of gastric ulcer. Eur J Pharmacol 1997, 332:209-13.

18. Rosowskij WJ, Jiang NY and Coy DH: Adrenomedullin, amylin, calcitonin gene-related peptide and their fragments are potent inhibitors of gastric acid secretion in rats. Eur J Pharmacol 1997, 336:61-3.

19. Zaki M, Koduru S, McCuen R, Vuyyuru L and Schubert ML: Amylin, released from the gastric fundus, stimulates somatostatin and thus inhibits histamine and acid secretion in mice. Gastroenterology 2002, 123:247-55.

20. Funakoshi A, Miyasaka K, Kitani K, Nakamura J, Funakoshi S, Fukuda H and Fuji N: Stimulatory effects of islet amyloid polypeptide (amylin) on exocrine pancreas and gastric release in conscious rats. Regul Pept 1992, 38:135-43.

21. Bhogal R, Smith DM and Bloom SR: Investigation and characterization of binding sites for islet amyloid polypeptide in rat membranes. Endocrinology 1992, 130:906-13.

22. Mulder H, Lindh AC, Esklad E, Westermark P and Sundler F: Islet amyloid polypeptide is expressed in endocrine cells of the gastric mucosa in the rat and mouse. Gastroenterology 1994, 107:712-9.

23. Tingsvoldt JE, Edlund H, Maden OD and Larsson LU: Gastric amylin expression. Cellular identity and lack of requirement for the homeobox protein PDX-1. A study in normal and PDX-1-deficient animals with a cautionary note on antisera evaluation. J Histochem Cytochem 1999, 47:973-80.

24. Giraud AS, Soll AH, Curtotta F and Walsh JH: Bombesin stimulation of gastrin release from canine gastrin cells in primary culture. Am J Physiol 1987, 252:G413-20.

25. Soll AH, Yamada T, Park J and Thomas LP: Release of somatostatin-like immunoreactivity from canine fundic mucosal cells in primary culture. Am J Physiol 1984, 247:G558-66.

26. Buchan AM, Curtis SB and Melochi RM: Release of somatostatin immunoreactivity from human antral D cells in culture. Gastroenterology 1990, 99:690-6.

27. Damholt AB, Buchan AM and Kofod H: Glucagon-like-peptide-1 secretion from canine L-cells is increased by glucose-dependent-insulinotropic peptide but unaffected by glucose. Endocrinology 1998, 139:2085-91.

28. Jordinson M, Beales I and Calam J: Soybean agglutinin stimulated cholecytokinin release from cultured rabbit jejunal cells requires calcium influx via L-type calcium channels. Peptides 1998, 19:1541-7.

29. Beales I, Blaser MJ, Srinivasan S, Calam J, Perez Perez GI, Yamada T, Scheiman J, Post L and Del Valle J: Effect of Helicobacter pylori products and recombinant cytokinins on gastrin release from cultured canine G cells. Gastroenterology 1997, 113:465-71.

30. Beales I, Calam J, Post L, Srinivasan S, Yamada T and Del Valle J: Effect of tumor necrosis factor-alpha and interleukin-8 on somatostatin release from canine fundic D-cells. Gastroenterology 1997, 112:136-43.

31. Ferrier GJ, Pierson AM, Jones PM, Bloom SR, Girgis SI and Legon S: Expression of the rat amylin (IAPP/DAP) gene. J Mol Endocrinol 1989, 3:R1-4.

32. Nicholl CG, Bhatdevaik JM, Mak J, Girgis SI and Legon S: Extra-pancreatic expression of the rat islet amyloid polypeptide (amylin) gene. J Mol Endocrinol 1992, 9:157-63.

33. Toshimori H, Narita R, Nakazato M, Asai J, Mitsukawa T, Kangawa K, Matsuo H and Matsukura S: Islet amyloid polypeptide (IAPP) in the gastrointestinal tract and pancreas of man and rat. Cell Tissue Res 1990, 262:401-6.

34. Soll AH, Amirian DA, Park J, Elshoff JD and Yamada T: Cholecystokinin potently releases somatostatin from canine fundic mucosal cells in short-term culture. Am J Physiol 1985, 248:G569-73.

35. DelValle J, Chia J, Park J and Yamada T: Distinct receptors for cholecystokinin and gastrin on canine fundic D-cells. Am J Physiol 1993, 264:G811-5.

36. Chiba T, Sugano K, Yamada T and Yamada T: Potential mediation of somatostatin secretion from canine fundic D-cells by protein kinase c. Am J Physiol 1987, 253:G62-7.
37. Chiba T, Raffoul K and Yamada T: Divergent stimulatory and inhibitory actions of carbamoylcholine on gastric D-cells. J Biol Chem 1987, 262:8467-9.
38. Chiba T, Fujita T and Yamada T: Carbachol inhibits stimulant-induced increases in fundic D-cell cytosolic Ca2+ concentration. Am J Physiol 1989, 257:G308-12.
39. Beales IL and Calam J: The histamine H3 receptor agonist N alpha-methylhistamine produced by Helicobacter pylori does not alter somatostatin release from cultured rabbit fundic D-cells. Gut 1998, 43:176-81.
40. Park J, Chiba T, Yokotani K, DelValle J and Yamada T: Somatostatin receptors on canine fundic D-cells: evidence for autocrine regulation of gastric somatostatin. Am J Physiol 1989, 257:G235-41.
41. Buchan AM, MacLeod MD, Meloche RM and Kwok YN: Muscarinic regulation of somatostatin release from primary cultures of human antral epithelial cells. Pharmacology 1992, 44:33-40.
42. Fehmann HC, Weber V, Goke R, Goke B and Arnold R: Cosecretion of amylin and insulin from isolated rat pancreas. FEBS Lett 1990, 262:279-81.
43. Stridsberg M, Sandler S and Wilander E: Cosecretion of islet amyloid polypeptide (IAPP) and insulin from isolated rat pancreatic islets following stimulation or inhibition of beta-cell function. Regul Pept 1993, 45:363-70.
44. Mulder H, Ahren B and Sundler F: Islet amyloid polypeptide and insulin gene expression are regulated in parallel by glucose in vivo in rats. Am J Physiol 1996, 271:E1008-14.
45. Mulder H, Ahren B and Sundler F: Islet amyloid polypeptide (amylin) and insulin are differentially expressed in chronic diabetes induced by streptozotocin in rats. Diabetologia 1996, 39:649-57.
46. Mulder H, Ahren B and Sundler F: Differential expression of islet amyloid polypeptide (amylin) and insulin in experimental diabetes in rodents. Mol Cell Endocrinol 1995, 114:101-9.
47. Schjoldager B, Mortensen PE, Christiansen J, Orskov C and Holst JJ: GLP-1 (glucagon-like peptide-1) and truncated GLP-1, fragments of human proglucagon, inhibit gastric acid secretion in man. Dig Dis Sci 1989, 34:703-8.
48. Beales IL and Calam J: Truncated glucagon-like peptide-1 and oxyntomodulin stimulate somatostatin release from rabbit fundic D-cells in primary culture. Exp Physiol 1996, 81:1039-41.
49. Rubinskas WJ, Cheng BL, Jiang NY and Coy DH: Examination of somatostatin involvement in the inhibitory action of GIP, GLP-1, amylin and adrenomedullin on gastric acid release using a new SRIF antagonist analogue. Br J Pharmacol 1998, 125:1081-7.
50. Beales IL and Calam J: Effect of Nalpha-methyl-histamine on acid secretion in isolated cultured rabbit parietal cells: implications for Helicobacter pylori associated gastritis and gastric physiology. Gut 1997, 40:14-9.